In Vivo Imaging and Tracking of Technetium-99m Labeled Bone Marrow Mesenchymal Stem Cells in Equine Tendinopathy
December 9th, 2015
9.2K views
This protocol describes the radiolabeling of equine mesenchymal stem cells and their implantation into tendon injuries in the horse in order to determine cell survival and tissue distribution using gamma scintigraphy.
Overview
This protocol describes the non-invasive tracking of equine mesenchymal stem cells after their implantation into tendon injuries using gamma scintigraphy. The technique allows for the assessment of cell survival and tissue distribution over time.
Key Study Components
Area of Science
- Stem Cell Therapy
- Veterinary Medicine
- Imaging Techniques
Background
- The fate of stem cells post-injection is not well understood.
- Gamma scintigraphy provides a method for tracking stem cells non-invasively.
- This technique has implications for treating tendinopathies and other diseases.
- Challenges include proper coordination of cells and patient setup.
Purpose of Study
- To track the distribution and fate of labeled mesenchymal stem cells.
- To enhance understanding of stem cell behavior in vivo.
- To explore potential applications in various therapeutic contexts.
Methods Used
- Application of acoustic coupling gel to the limb.
- Use of a linear transducer for imaging.
- Systematic scanning of the Palmer metacarpal region.
- Identification of the maximal injury zone through imaging.
Main Results
- Successful tracking of stem cells to multiple organs.
- Insight into the survival and distribution of stem cells post-implantation.
- Demonstrated the feasibility of using gamma scintigraphy in veterinary applications.
- Provided a foundation for further research in stem cell therapies.
Conclusions
- The protocol allows for effective monitoring of stem cell therapies.
- Gamma scintigraphy is a valuable tool in veterinary medicine.
- Further studies are needed to explore broader applications.
Frequently Asked Questions
What is gamma scintigraphy?
Gamma scintigraphy is a non-invasive imaging technique used to track the distribution of radiolabeled substances in the body.
How are mesenchymal stem cells labeled?
Mesenchymal stem cells are labeled using a radiolabeling technique that allows for their tracking post-implantation.
What are the advantages of using this protocol?
The protocol allows for non-invasive tracking of stem cells, providing insights into their survival and distribution.
What challenges might researchers face?
Challenges include coordinating the cells for labeling and setting up the imaging process effectively.
Can this method be applied to other diseases?
Yes, the technique could be adapted for investigating therapies for bone and cardiac diseases.
What is the significance of the short half-life of the radiolabel?
The short half-life ensures that the radiolabel is cleared from the body within 48 hours, minimizing long-term exposure.
Executive Industry Relevance
Non-invasive tracking of stem cell fate addresses a critical gap in regenerative medicine development by enabling quantitative assessment of cell retention and biodistribution. This capability supports mechanistic de-risking in preclinical stem cell therapies by clarifying early survival kinetics and off-target migration patterns. For equine and translational tendon injury models, such imaging informs go/no-go decisions by linking cellular persistence to functional outcomes.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by quantifying stem cell retention at injury sites versus clearance to organs like lungs and thyroid.
- Operational Value: Provides reproducible biodistribution data using gamma scintigraphy to compare administration routes such as intralesional delivery versus regional perfusion.
Screening & Assay Development
- Scientific Value: Generates quantitative dependent variable measurements (gamma counts over standardized regions of interest) to assess cell labeling efficiency and short-term survival.
- Operational Value: Establishes a standardized workflow for radiolabeling mesenchymal stem cells with Tc-99m HMPAO, supporting assay readiness for comparative studies.
Translational & Preclinical Research
- Scientific Value: Supports disease-relevant system validation by tracking cell persistence up to 36 hours post-implantation in equine tendinopathy, informing dose and timing considerations.
- Operational Value: Facilitates cross-functional collaboration through standardized region-of-interest analysis and replication requirements for longitudinal imaging time points.
Pipeline & Workflow Integration
This imaging method fits within the discovery continuum from early target validation through preclinical assessment, providing quantitative biodistribution readouts that help prioritize stem cell delivery strategies before functional efficacy testing.
- Discovery Biology: Supports hypothesis testing by enabling visualization of stem cell fate and quantification of lesion retention versus pulmonary or thyroid uptake.
- Screening: Delivers assay-standardized, quantitative outputs (region-of-interest counts) that allow comparison of cell viability under different handling or delivery conditions.
- Analytics: Enables calculation of percent decrease in signal over time to distinguish radiolabel decay from biological clearance, aiding kinetic modeling.
- Translational Research: Connects early engraftment data to preclinical continuity by identifying optimal windows for assessing functional repair in tendon injury models.
- Enterprise Reuse: Establishes a reusable non-invasive imaging platform applicable to stem cell studies in multiple tissue contexts, including bone and cardiac disease models.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity in stem cell therapy by providing direct evidence of biodistribution and early survival kinetics.
- Operational Value: Ensures reproducibility through standardized cell washing, labeling, and imaging protocols with lead-shielded handling.
- Strategic Value: Improves go/no-go decisions by quantifying early cell loss (<10% retention) and organ-specific biodistribution patterns.
- Portfolio Impact: Enables risk-adjusted advancement decisions by clarifying whether observed therapeutic effects correlate with sustained local engraftment versus transient paracrine activity.
Implementation Considerations
- Requires expertise in radiopharmacy and safe handling of Tc-99m under radiation safety protocols.
- Depends on access to gamma scintigraphy instrumentation and lead-shielded workspaces for cell labeling and injection procedures.
- Necessitates cross-team standardization between cell processing, imaging, and veterinary surgery teams for consistent region-of-interest definition.
- Involves adaptation considerations when translating labeling efficiency from equine MSCs to other species or cell sources.
- Limited to short-term tracking (up to 36 hours) due to the 6-hour half-life of Tc-99m, restricting assessment of long-term engraftment beyond this window.
Biopharma FAQs
Why does percent decrease in gamma counts matter for target validation?
Quantifying the percent decrease in gamma counts over time distinguishes radiolabel decay from biological clearance, enabling accurate calculation of stem cell persistence at the injection site. This measurement supports target validation by revealing whether retained cells correlate with functional tendon repair.
How does isolation of the injection site as an independent variable fit the discovery pipeline?
By comparing intralesional delivery to regional perfusion via the digital palmar vein, the protocol isolates the administration route as an independent variable to assess its impact on cell retention and lung signal intensity. This approach fits the discovery pipeline by clarifying how delivery method influences early biodistribution patterns.
What do quantitative dependent variable measurements enable in stem cell tracking?
Quantitative dependent variable measurements—such as gamma counts over standardized regions of interest in the lesion, lungs, and thyroid—enable objective comparison of cell distribution across administration routes and time points. These outputs support assay development by providing reproducible, numerical readouts for screening stem cell viability under different conditions.
Why do replication requirements matter for cross-functional collaboration?
Replication requirements—such as recording identically sized regions of interest for each animal at different time points—ensure consistency in quantitative data collection across teams. This standardization enables reliable cross-functional collaboration between imaging, cell processing, and veterinary surgery groups by minimizing variability in biodistribution assessment.
What statistical analysis capabilities are required before implementing gamma scintigraphy for stem cell tracking?
Implementing this technique requires the capability to calculate percent decrease in counts from baseline to correct for radiolabel decay, as well as to perform region-of-interest analysis using ellipse tools to standardize quantification. These statistical capabilities are essential for distinguishing biological clearance from physical decay and ensuring accurate longitudinal tracking.
Chapters in this video
0:05
Title
1:01
Equine Forelimb Tendon Ultrasonography and Mesenchymal Stem Cell Tc-99m Labeling
3:31
Tc-99m-HMPAO-labeled Cell Intralesional Implantation
4:29
Gamma Scintigraphy Imaging
5:24
Results: Representative Recorded Radioactivity after Intralesional Injection
6:54
Conclusion
